A targeted DNA vaccine encoding Fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis

Journal of Clinical Investigation

Volumn 106, Issue 5, 2000, Pages 671-679

  Wildbaum, Gizi ^a   Westermann, Juergen ^a   Maor, Gila ^b   Karin, Nathan ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE; DNA VACCINE; FAS ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

EID: 0033818187     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8759     Document Type: Article

References (43)

1. Nagata, S., and Goldstein, G. 1995. The FAS death factor. Science. 267:1449-1455.
2. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., and Ferguson, T.A. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
3. Suda, T., et al. 1995. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154:3806-3813.
4. Watanabe-Fukunaga, R., et al. 1992. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148:1274-1279.
5. Bossi, G., and Griffiths, G.M. 1999. Degranulation plays an essential part in regulation cell surface expression of Fas ligand in T cells and natural killer cells. Nat. Med. 5:90-96.
6. Alvord, E.C., Jr. 1984. The challenge: how good a model of MS is EAE today? Prog. Clin. Biol. Res. 146:3-5.
7. MacFarlin, D., and MacFarland, H. 1983. Multiple sclerosis. N. Engl. J. Med. 307:1183-1188.
8. Yednock, T.A., et al. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 356:63-66,
9. Karin, N., Szafer, F., Mitchell, D., Gold, D.P., and Steinman, L. 1993. Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. J. Immunol. 150:4116-4124.
10. Ruddle, N.H., et al. 1990. An antibody to lymphotoxin and tumor necrosis factot prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193-1200.
11. Selmaj, K., Papierz, W., Glabinski, A., and Kohno, T. 1995. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56:135-141.
12. Leonard, J.P., Waldburger, K.E., and Goldman, S.J. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181:381-386.
13. Wildbaum, G., Youssef, S., Grabie, N., and Karin, N. 1998. Prevention of experimental autoimmune encephalomyelitis by antibodies to interferon gamma inducing factor. J. Immunol. 161:6368-6374.
14. Suvannavejh, G.C., Dal Canto, M.C., Matis, L.A., and Miller, S.D. 2000. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 105:223-231.
15. Sabelko-Downes, K.A., Cross, A.M., and Russell, J.H. 1999. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J. Exp. Med. 189:1195-1205.
16. Chervonsky, A.V., et al. 1997. The role of Fas in autoimmune diabetes. Cell. 89:17-24.
17. Itoh, N., et al. 1997. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186:613-618.
18. Lau, H.T., and Stoeckert, C.J. 1997. FasL: too much of a good thing? Transplanted grafts of pancreatic islet cells engineered to express Fas ligand are destroyed not protected by the immune system. Nat. Med. 3:727-728.
19. Thilenius, A.R.B., Sabelko-Dowens, K.A., and Russell, J.H. 1999. The role of the antigen presenting cell in Fas-mediated direct and bystander killing: potential in vivo function in experimental allergic encephalomyelitis. J. Immunol. 162:643-650.
20. Waldner, H., Sobel, R.A. Howard, E., and Kuchroo, V.K. 1997. Fas and FasL deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159:3100-3103.
21. Sabelko, K.A., Kelly, K.A., Nahm, M.H., Cross, A.H., and Russell, J.H. 1997. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159:3096-3099.
22. Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A., and Nagata, S. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:314-317.
23. Chen, J.J., Sun, Y., and Nabel, G.J. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 282:1714-1717.
24. Nagata, S. 1996. Fas ligand and immune evasion. Nat. Med. 2:1306-1307.
25. Youssef, S., et al. 1998. Long lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol. 161:3870-3879.
26. Gijbels, K., et al. 1993. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 36:432-440.
27. Silvius, J.R. 1992. Solubilization and functional reconstitution of biomembrane components. Annu. Res. Biophys. Biomol. Struct. 21:323-348.
28. Hogger, P., Dreier, J., Droste, A., Buck, F., and Sorg, C. 1998. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J. Immunol. 161:1883-1890.
29. Wildnaum, G., and Karin, N. 1999. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-α) by targeted DNA vaccine confers long lasting resistance to experimental autoimmune encephalomyelitis. Gene Ther. 6:1128-1138.
30. Bemelmans, M.H., Gouma, D.J., and Buurman, W.A. 1993. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. J. Immunol. 151:5554-5562.
31. Westermann, J., et al. 1996. Blood leukocyte subsets of the rat: expression of adhesion molecules and localization within high endothelial venules. Scand. J. Immunol. 43:297-303.
32. Bonetti, B., and Raine, C.S. 1997, Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoprosis. Ann. Neurol. 42:74-84.
33. Schmied, M., et al. 1993. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis: evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathol. 143:446-451.
34. Bonetti, B., Pohl, J., Gao, Y.L., and Raine, C.S. 1997. Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J. Immunol. 159:5733-5741.
35. Pitt, D., Werner, P., and Raine, C.S. 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med 6:67-70.
36. Youssef, S., Wildbaum, G., and Karin, N. 1999. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines. J. Antoimmun. 13:21-29.
37. Raz, H., et al. 1996. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunisation. Proc Natl. Acad. Sci. USA. 93:5141-5145.
38. Sato, Y., et al. 1996. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:352-357.
39. Cyster, J.G., Hartley, S.B., and Goodnow, C.C. 1994. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature. 371:389-395.
40. Dowling, P., et al. 1996. Involvement of the CD95 (APO-1/Fas) recepror/ligand system in multiple sclerosis brain. J. Exp. Med. 184:1513-1518.
41. D'Souza, S.D., et al. 1996. Multiple sclerosis: Fas signaling in oligoden-drocyte cell death. J. Exp. Med. 184:2361-2370.
42. Bellingan, G.J., Caldwell, H., Howie, S.B., Dransfield, I., and Haslett, C. 1996. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J. Immunol. 157:2577-2585.
43. Zhang, X., et al. 1997. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J. Exp. Med. 185:1837-1849.